Plain-English translation of NCT07097207 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called CD19CD20-CAR.p40-T, which is made from your own immune cells that are engineered in a lab to recognize and attack cancer cells. The treatment is designed for people whose B-cell lymphoma has come back or stopped responding to standard chemotherapy. Researchers want to see how safe the treatment is and how well it works.
Many patients with B-cell lymphoma stop responding to standard treatments, leaving few good options. This medication represents a newer approach that uses your body's own immune system to fight the cancer in a more targeted way.
You likely qualify if…
You likely don't qualify if…
You would first receive chemotherapy (fludarabine and cyclophosphamide) for 3 days to prepare your body. Three days later, you would receive a single intravenous infusion of the engineered cells. The trial tracks your safety closely for 30 days after the infusion, then monitors how well the treatment works and how long it lasts over 6 months. You'll have blood tests and imaging scans to check your progress.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China